A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855) [EXTENSION OF 700220875]

Trial Profile

A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855) [EXTENSION OF 700220875]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Retigabine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
    • 19 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 19 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top